I agree with mrhodes. Dr O'Conner's body language and face perked up at the mention of drugs, both the current drugs in use and new ones on the way.
And I’m not surprised either at the Canadian & American MS Societies responses. It’s called restraint and covering their ass. They have to be cautious, and I can understand that. CCSVI is new, we have more work to be done, more Liberation Procedures to do, more research & trials.
I will do my part, if I can get the tests and if I have stenosis in my veins. I’ll pay and have the procedure and monitor my post-op.
I feel Dr. Dake and Stanford where smart to take a backseat at the moment. I think we need to hear from the nay-sayer’s so we know where the weak spots are in our presentations and research. After all, in the MS treatment/research department CCSVI is in it’s infancy.
But I don’t get me wrong, I don’t want any grass to grow either between now and PROVING
without a doubt that Dr. Zamboni is correct!
We can’t forget what a Money Making disease this is for many aspects of the medical/pharmaceutical communities. Here is an article skewed to folks that want to make money off our disease. And in today’s economy, no one wants to loose their “cash cow”!
Examine The Global Multiple Sclerosis Market 2009-2024
http://www.pr-inside.com/examine-the-gl ... 213395.htm
Some excerpts to get your blood boiling and your face red!
"The prevalence and onset of MS in children and adults is expected to rise steadily. Global sales for MS therapies will rise accordingly, due to epidemiological, healthcare and commercial drivers.
This report answers those important questions and others, such as how the established MS products will fare competitively in the years ahead. Which will remain the most profitable and how will they be affected by new competition.
The Global Multiple Sclerosis Market 2009-2024 commercially analyses both leading and emergent treatments, with key companies and products discussed comprehensively. In particular, we discuss prospects for the following MS drugs: - Tysabri - Avonex - Copaxone - Betaferon - Rebif.
Predicted revenues, growth rates and other key metrics for the global MS drugs market from 2009 to 2024 Predicted revenues, growth rates and other key metrics for leading MS drugs worldwide from 2009 to 2024 Predicted revenues, growth rates and other key metrics for MS drug sales in leading nations from 2009 to 2024
Visiongain predicts that total revenues in the MS market will increase steadily throughout the forecast period, 2009 to 2024, with the most substantial growth occurring during a crucial period in the future."
Well, I beg to differ with them if CCSVI gets off the ground. They’ll be building their castles and empires in the sand!!!!!
As some of our Aussie posters might say: "That would make my day, mate!"